Trial · NCT04635059

Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

NCT04635059, Phase 2, Terminated, Medical College of Wisconsin; results first posted 2024-12-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer. Trials, record NCT04635059. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04635059

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
NCT number: NCT04635059
Status: Terminated
Phases: Phase 2
Enrollment: 6 participants, actual
Lead sponsor: Medical College of Wisconsin
Conditions: Prostate Cancer
Interventions: Pacritinib
First posted: 2020-11-18
Last updated: 2025-11-17
Results first posted: 2024-12-17

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Number of Patients With Six-month PSA Progression-free Survival.	Six months	PSA progression-free survival is defined as the length of time that a subject will be alive and free from PSA progression per PCWG3 guidelines.
Secondary	PSA Levels	Cycle1Day1 (month 0), every month up to month 4.	PSA level in blood is measured in units of nanograms per milliliter.
Secondary	Testosterone Measurement	Baseline and three months	Serum testosterone will be measured in nanograms per deciliter.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Number of Patients With Six-month PSA Progression-free Survival.	Six months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	PSA Levels	Cycle1Day1 (month 0), every month up to month 4.	Two subjects were not tested in month 4.	ng/mL	MEAN
SECONDARY	Testosterone Measurement	Baseline and three months	Two subjects were not tested in month 3.	ng/dL	MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
The Number of Patients With Six-month PSA Progression-free Survival.	Pacritinib		0		Participants
PSA Levels	Pacritinib	PSA at C1D1 (month 0), ng/mL	1.9	Standard Deviation .5	ng/mL
PSA Levels	Pacritinib	PSA at month 1, ng/mL	3.2	Standard Deviation .8	ng/mL
PSA Levels	Pacritinib	PSA at month 2, ng/mL	4.1	Standard Deviation 1.3	ng/mL
PSA Levels	Pacritinib	PSA at month 3, ng/mL	4.7	Standard Deviation .8	ng/mL
PSA Levels	Pacritinib	PSA at month 4, ng/mL	5.7	Standard Deviation .3	ng/mL
Testosterone Measurement	Pacritinib	Testosterone at screening, ng/dL	390	Standard Deviation 280	ng/dL
Testosterone Measurement	Pacritinib	Testosterone at 3 months, ng/dL	330	Standard Deviation 181	ng/dL

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pacritinib	6
Overall Study	COMPLETED	Pacritinib	2
Overall Study	NOT COMPLETED	Pacritinib	4

Source ClinicalTrials.gov

Adverse events56

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Alanine aminotransferase increased	Investigations	Pacritinib	1	6	2
other	Alkaline phosphatase increased	Investigations	Pacritinib	1	6	1
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	Pacritinib	1	6	1
other	Anorexia	Metabolism and nutrition disorders	Pacritinib	1	6	1
other	Arthralgia	Musculoskeletal and connective tissue disorders	Pacritinib	1	6	1
other	Aspartate aminotransferase increased	Investigations	Pacritinib	1	6	1
other	Atrial fibrillation	Cardiac disorders	Pacritinib	1	6	1
other	Back pain	Musculoskeletal and connective tissue disorders	Pacritinib	2	6	2
other	Bladder spasm	Renal and urinary disorders	Pacritinib	1	6	1
other	Belching	Gastrointestinal disorders	Pacritinib	1	6	1

1 to 10 of 56Source ClinicalTrials.gov

See all 56 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pacritinib	0	6
Total, other adverse events	Pacritinib	6	6
Total, serious adverse events	Pacritinib	0	6

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04635059

GET https://conductscience.org/api/trials/v1/NCT04635059/events?page=2

API reference For AI assistants